About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.

At the moment the company generates 13M USD in revenues.

On its last earning announcement, the company reported a loss of -0.28$ per share.

The book value per share is 0.69$

Catalyst Pharmaceuticals, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
13M - -30M -234.40% -29M -0.28 - - 103M 0.69 -28M - -28M